We serve Chemical Name:5-Bromo-3-(phenylsulfanyl)-1H-pyrrolo[2,3-b]pyridine CAS:918511-67-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![5-Bromo-3-(phenylsulfanyl)-1H-pyrrolo[2,3-b]pyridine](https://a.dearchem.com/CAS2/918511-67-8.png)
Chemical Name:5-Bromo-3-(phenylsulfanyl)-1H-pyrrolo[2,3-b]pyridine
CAS.NO:918511-67-8
Synonyms:5-Bromo-3-(phenylsulfanyl)-1H-pyrrolo[2,3-b]pyridine
Molecular Formula:C13H9BrN2S
Molecular Weight:305.19300
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:53.98000
Exact Mass:303.96700
LogP:4.47660
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-Bromo-3-(phenylsulfanyl)-1H-pyrrolo[2,3-b]pyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Bromo-3-(phenylsulfanyl)-1H-pyrrolo[2,3-b]pyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Bromo-3-(phenylsulfanyl)-1H-pyrrolo[2,3-b]pyridine Use and application,5-Bromo-3-(phenylsulfanyl)-1H-pyrrolo[2,3-b]pyridine technical grade,usp/ep/jp grade.
Related News: The mode of cooperation between domestic API companies and large international companies can lower the export threshold. 5-Bromo-3-(phenylsulfanyl)-1H-pyrrolo[2,3-b]pyridine manufacturer Like Altasciences, Alira has also placed an emphasis on the preclinical setting in recent months with its March hire of Nikole Siegmund as vice president of preclinical development. 5-Bromo-3-(phenylsulfanyl)-1H-pyrrolo[2,3-b]pyridine supplier Like Altasciences, Alira has also placed an emphasis on the preclinical setting in recent months with its March hire of Nikole Siegmund as vice president of preclinical development. 5-Bromo-3-(phenylsulfanyl)-1H-pyrrolo[2,3-b]pyridine vendor When they do design their phase 3, they’re going to need to be better about that part of the study design, and really focus on enrolling individuals that have the right biomarkers to be able to look at not only the safety and tolerability but also the efficacy on cognition and function,” Edelmayer said.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau. 5-Bromo-3-(phenylsulfanyl)-1H-pyrrolo[2,3-b]pyridine factory he agency said the drugmaker and Emergent must agree that the FDA can share relevant information about the manufacturing of the doses with regulators where the vaccine is shipped.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau. 5-Bromo-3-(phenylsulfanyl)-1H-pyrrolo[2,3-b]pyridine factory he agency said the drugmaker and Emergent must agree that the FDA can share relevant information about the manufacturing of the doses with regulators where the vaccine is shipped.
